On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

USC Norris Comprehensive Cancer Center

InstitutionResearch output, impact & collaborations

USC Norris Comprehensive Cancer Center is a institution indexed in ScholarIQ from OpenAlex.

What is known about USC Norris Comprehensive Cancer Center?

ScholarIQrecord summary

USC Norris Comprehensive Cancer Center is a research organisation in Los Angeles, US. OpenAlex records 6,407 works and 747,807 citations for it. 908 researchers list it as their most recent affiliation.

How many works does USC Norris Comprehensive Cancer Center have?

ScholarIQindexed works

USC Norris Comprehensive Cancer Center has 6,407 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does USC Norris Comprehensive Cancer Center have?

ScholarIQcitation count

USC Norris Comprehensive Cancer Center has 747,807 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at USC Norris Comprehensive Cancer Center?

ScholarIQresearcher count

USC Norris Comprehensive Cancer Center has 908 researchers in the ScholarIQ index.

What is the average h-index at USC Norris Comprehensive Cancer Center?

ScholarIQavg h-index

USC Norris Comprehensive Cancer Center has an average h-index of 92.5 in OpenAlex.

What is the ROR of USC Norris Comprehensive Cancer Center?

ScholarIQror

The ROR for USC Norris Comprehensive Cancer Center is on the source record.

What is the OpenAlex record for USC Norris Comprehensive Cancer Center?

ScholarIQopenalex

The OpenAlex for USC Norris Comprehensive Cancer Center is on the source record.

Who are the most-cited researchers behind USC Norris Comprehensive Cancer Center?

ScholarIQtop researchers by citations
1
Susan Groshen · Prostate Cancer Treatment and Research
794 works43,393 citations
2
David I. Quinn · Prostate Cancer Treatment and Research
830 works28,589 citations

What are the most-cited papers on USC Norris Comprehensive Cancer Center?

ScholarIQmost cited works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
New England Journal of Medicine. 20173,424 CitationsOPEN ACCESS
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain, Catherine M. Tangen, Donna L. Berry, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen M. Prescott, S.K. Sundaram, Eric J. Small, Nancy A. Dawson, Bryan Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Benjamin Ely, Carol M. Moinpour, Nicholas J. Vogelzang, Ian M. Thompson
New England Journal of Medicine. 2013574 CitationsOPEN ACCESS
Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease
Min Wei, Sebastian Brandhorst, Mahshid Shelehchi, Hamed Mirzaei, Chia Wei Cheng, J. Budniak, Susan Groshen, Wendy J. Mack, Esra Guen, Stefano Di Biase, Pinchas Cohen, Todd E. Morgan, Tanya B. Dorff, Kurt Hong, Andreas Michalsen, Alessandro Laviano, Valter D. Longo
Science Translational Medicine. 2017574 CitationsOPEN ACCESS
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Louis M. Fink, Tong Xu, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci, J. Paul Monk, Ram H. Datar, Mark Garzotto, Philip C. Mack, Primo N. Lara, Celestia S. Higano, Maha Hussain, Ian M. Thompson, Richard J. Côté, Nicholas J. Vogelzang
Journal of Clinical Oncology. 2014334 CitationsOPEN ACCESS
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz
The Lancet Oncology. 2022284 CitationsOPEN ACCESS

How much of the research on USC Norris Comprehensive Cancer Center is open access?

ScholarIQopen access share
100%OPEN ACCESS
Gold
0%
Green
33%
Hybrid
17%
Bronze
50%
Closed
0%

Related on ScholarIQ

470M+ articles · 14-day free trial